Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
7 hedge funds and large institutions have $189K invested in Biostar Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
43% less capital invested
Capital invested by funds: $330K → $189K (-$141K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.77K |
| 2 |
Barclays
London,
United Kingdom
|
+$1.39K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$53.3K |
| 2 |
JP Morgan Chase
New York
|
-$34.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.74K |
| 4 |
Morgan Stanley
New York
|
-$588 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $72K | -$588 | -224 | -0.7% |
|
|
2
JP Morgan Chase
New York
| $68K | -$34.6K | -13,195 | -31% |
|
|
AIM
3
Acrospire Investment Management
Chicago,
Illinois
| $27K | -$53.3K | -20,279 | -63% |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| $18K | +$9.77K | +3,719 | +89% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2K | -$3.74K | -1,424 | -59% |
|
|
6
Barclays
London,
United Kingdom
| $2K | +$1.39K | +530 | +113% |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$1.05K | +400 | +40,000% |
|
BSPM Hedge Fund Activity: Q1 2017 in Review
7 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q1 2017, worth a combined $189K — down 43% from $330K a quarter earlier.
Fund positioning in BSPM was balanced in Q1 2017: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $9.77K. The largest seller was Acrospire Investment Management, cutting an estimated $53.3K.
- 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $189K of Biostar Pharmaceuticals, Inc. stock for Q1 2017, down 43% quarter-over-quarter.
- 0 funds opened new Biostar Pharmaceuticals, Inc. positions in Q1 2017 and 0 closed out.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q1 2017 was Acadian Asset Management, an estimated $9.77K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q1 2017 was Acrospire Investment Management, an estimated $53.3K sold.
Based on aggregated 13F filings for Q1 2017.